Diligence memo · auto-generated · as of July 3, 2026

Arteriocyte Medical Systems Inc

Arteriocyte Medical Systems Inc looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Arteriocyte Medical Systems Inc operates in Other Health Care, based in Cleveland.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Arteriocyte Medical Systems Inc has raised $250K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $150K on 2011-03-08.

Most recent recorded round closed around 2011-03-08.

Valuation (modeled)modeled

Provath models Arteriocyte Medical Systems Inc at approximately $4.6M (range $94K–$52M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.50× the median modeled value of Pre-Seed Other Health Care companies in 2010–2012 (351 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 20 months.

Last raise 15.3 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.5× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 12% of Other Health Care peers (5377 compared).

Modeled value ranks above 20% of those peers.

Closest niche peers: Chrysallis, Inc., RefillDRS, LLC, Ageology LLC, Great Lakes Healthcare Fund I, LLC, CreateHealth, Inc..

Peoplefiled

4 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.